BAYER reported encouraging sales for the quarter aided by strong demand for new cancer and kidney medicines.
Group revenue reached 11.1 billion euros (S$16.1 billion) in the second quarter, the German company said in a statement on Tuesday (Aug 6), ahead of the 10.9 billion euros average of analysts’ estimates. Bayer reiterated its 2024 earnings forecast.
Chief executive officer Bill Anderson is trying to win back the confidence of investors following years of crisis at the German conglomerate. The Texas native joined Bayer last spring and has bet his tenure on the premise that the best way to revive the company’s fortunes is to improve its three divisions – which are focused on pharmaceuticals, consumer health and agriculture – rather than split them apart.
Anderson has also cut jobs and made other changes intended to improve competitiveness in each of Bayer’s businesses. The company has 3,200 fewer jobs now than when the year began, he said in prepared remarks.
The shares were little changed when markets opened. The stock had fallen 48 per cent in the last 12 months through Monday’s close and more than 70 per cent since Bayer acquired Monsanto in 2018.
Bright spots
Each of the divisions had bright spots in the second quarter. The crop science business posted sales of nearly 5 billion euros, slightly ahead of estimates, thanks in part to robust North American demand for glyphosate-based products like the controversial weedkiller Roundup.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Consumer health, Bayer’s smallest unit, performed roughly in line with expectations. It saw strong demand for digestive health products, offsetting weaker sales of allergy and cold medicines, the company said.
Bayer’s pharma division was the biggest surprise on the sales front, thanks to growing demand for its new drugs, Nubeqa for cancer and kidney medicine Kerendia. Meanwhile, older eye medicine Eylea topped estimates with higher sales. Bayer is facing new competition for that medicine along with its older blockbuster blood thinner, Xarelto.
Bayer raised its 2024 sales outlook for the pharma unit. It now expects revenue to stay flat or even grow slightly, better than the previous guidance that anticipated falling sales.
“As always with Bayer, it’s a mixed bag but given weak crop results from peers and strong pharma performance/upgrade, we think this will be taken relatively well,” Barclays analysts said in a note.
The company faces plenty of challenges ahead. Among other things, it’s grappling with litigation in the US for products like the herbicide Roundup, which it inherited with the US$63 billion Monsanto takeover in 2018. Plaintiffs claim the product causes cancer, while Bayer insists it’s safe. BLOOMBERG
